Skip to main content
BioInvent International logo

BioInvent International — Investor Relations & Filings

Ticker · BINV ISIN · SE0015244520 LEI · 549300E7QRHEF2IJUY10 ST Manufacturing
Open in API
Filings indexed 679 across all filing types
Latest filing 2018-11-20 Regulatory Filings
Country SE Sweden
Listing ST BINV

About BioInvent International

https://www.bioinvent.com/en

BioInvent International is a clinical-stage company that discovers and develops novel, first-in-class immuno-modulatory antibodies for cancer therapy. Leveraging extensive expertise in immunology, cancer biology, and antibody biology, the company generates innovative immuno-oncology drug candidates for its clinical pipeline. BioInvent's operations include an in-house manufacturing facility to produce antibodies for its preclinical studies and clinical trials, with the goal of developing treatments that can transform the lives of cancer patients.

Recent filings

Filing Released Lang Actions
BioInvent ingår tillverkningsavtal med amerikanskt cellterapiföretag
Regulatory Filings Classification · 96% confidence The document is a press release dated November 20, 2018, announcing that BioInvent International AB has entered into a manufacturing agreement with an unnamed US cell therapy company for cGMP material production, expected to generate $1.5 million in revenue. The text concludes with a statement that this information is required to be disclosed under the EU Market Abuse Regulation (MAR) and was made public on November 20, 2018. This structure—a brief announcement of a significant business event (a contract/financing activity) followed by boilerplate company information and a regulatory disclosure statement—is characteristic of a general regulatory announcement or press release that doesn't fit a more specific financial report category (like 10-K, ER, or IR). Since it details a financing/contractual event generating revenue, it relates to capital/financing activities, but the primary nature is a general corporate update disclosed via regulatory channels. Given the options, 'Capital/Financing Update' (CAP) is relevant due to the $1.5M revenue expectation from the contract, but 'Regulatory Filings' (RNS) is often used for general, non-standardized corporate news releases that fulfill disclosure requirements but aren't formal SEC/exchange reports. However, the content is specifically about securing a manufacturing contract and associated revenue, which strongly aligns with 'Capital/Financing Update' (CAP) as it impacts future financial structure/revenue generation, even if it's not a formal capital raise. Given the specific nature of the announcement (a manufacturing contract generating revenue), CAP is a better fit than the general RNS fallback, although RNS is also plausible for a MAR disclosure.
2018-11-20 Swedish
Major Shareholding Notification 2018
Major Shareholding Notification Classification · 99% confidence The document explicitly details the holdings of a specific 'Holder' (Compagnie Merieux Alliance) in the 'Issuer' (BioInvent International Aktiebolag), showing the 'Number of underlying shares' (27,561,395) and the resulting 'Percentage of voting rights' (7.85673 %). The structure, use of terms like 'major shareholding notification', and the focus on voting rights percentage clearly indicate a filing related to changes in significant ownership thresholds. This aligns directly with the definition for Major Shareholding Notification (MRQ). The document is not a full annual report (10-K), an earnings release (ER), or a proxy statement (DEF 14A/PSI).
2018-11-12 English
Interim / Quarterly Report 2018
Interim / Quarterly Report Classification · 100% confidence The document is a quarterly financial report ('delårsrapport') for BioInvent covering the period from January to September 2018. It contains detailed financial statements, income statements, cash flow analysis, and management commentary on business operations and clinical pipeline progress. It meets the criteria for an Interim/Quarterly Report (IR) as it provides substantive financial data and analysis for a period shorter than a full fiscal year. 9M 2018
2018-10-24 Swedish
Interim / Quarterly Report 2018
Interim / Quarterly Report Classification · 100% confidence The document is titled 'BioInvent Interim Report January 1 – September 30, 2018'. It contains comprehensive financial data, including net sales, loss after tax, cash flow, and detailed breakdowns of research and development costs for the third quarter and the nine-month period. It also includes management commentary and business updates. As it is a comprehensive financial report for a period shorter than a full fiscal year, it fits the definition of an Interim/Quarterly Report (IR). 9M 2018
2018-10-24 English
BioInvent ingår licens- och tillverkningsavtal med CardioVax avseende utveckling av orticumab
M&A Activity Classification · 99% confidence The document is a 'PRESSMEDDELANDE' (Press Release) dated September 27, 2018, announcing that BioInvent has entered into a licensing and manufacturing agreement with CardioVax regarding the drug candidate orticumab. It details short-term manufacturing revenue and long-term royalty potential. This type of announcement, which details a significant business transaction (licensing/partnership) but is not a formal regulatory filing like a 10-K or a specific financial report (ER, IR), fits best under the general category for significant corporate news that isn't covered by other specific codes. Since it is a press release announcing a major business development (licensing/financing aspect), it is most closely related to Capital/Financing Update (CAP) or a general Regulatory Filing (RNS). Given the nature of the announcement—a licensing deal generating future revenue—it is a significant corporate event. However, since it is a press release announcing a business deal rather than a formal filing detailing capital structure changes (CAP) or a general regulatory disclosure (RNS), and it doesn't fit ER, IR, or LTR, RNS (Regulatory Filings/General Announcement) is the most appropriate fallback for a non-standard, material press release, although 'CAP' could also be considered due to the revenue/royalty structure. Given the context of a press release announcing a material business agreement, RNS is the safest general classification for non-standard announcements.
2018-09-27 Swedish
BioInvent signs licensing and manufacturing agreement with CardioVax for the development of orticumab
Regulatory Filings Classification · 95% confidence The document is a press release announcing a specific corporate event: a licensing and manufacturing agreement signed between BioInvent and CardioVax regarding the drug orticumab. It details financial expectations (revenue, royalties) and provides company background. This type of announcement, which details a significant business transaction or partnership outside of standard periodic financial reporting (like 10-K or IR), typically falls under general corporate news or regulatory filings. Since it is not a formal financial report (10-K, IR, ER, MRQ), nor a management change (MANG), nor a capital action (CAP, SHA, POS), nor a dividend notice (DIV), the most appropriate classification is the general regulatory announcement category, RNS, as it is a material event disclosed to the market, often mandated by regulations like the EU Market Abuse Regulation mentioned at the end.
2018-09-27 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.